FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
MannKind stock rose after the FDA approved Furoscix ReadyFlow, as the company also announced a $50 million private placement financing.
A medicine company got permission to sell a new heart and kidney medicine that people can use at home. This approval shows the company made something doctors wanted, which is a positive sign about whether their work is helping people.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.